Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)

Starting soon · Not applicable

Conditions studied: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis

In brief

The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction associated steatotic liver disease (MASLD) and/or cirrhosis, in patients undergoing routine transthoracic echocardiograms (TTEs). The main question it aims to answer is to: 1. Evaluate notification responsiveness and rates of confirmatory testing for patients identified as high risk for having liver disease to determine whether optimized notifications increase timely confirmatory testing and treatment initiation versus standard of care assessment. 2. Compare time to diagnosis, treatment uptake, and clinical outcomes (hospitalizations, incident ASCVD, mortality) between cohorts identified as high risk by the AI algorithm and comparison groups to determine whether AI guided screening shortens time to diagnosis and increases appropriate treatment.

Key facts

Study ID

NCT07216859

Run by

Kaiser Permanente

People needed

2000

Starts

2026-01-01

Expected to finish

2027-11-01

Last updated by the study team

2025-11-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults ≥18 years.
• Underwent routine TTE within site defined recent timeframe and flagged as high risk for MASLD and/or cirrhosis by the AI model using pre specified threshold.
• Able to provide informed consent; reachable for follow up.

You may not qualify if…

• Inability to consent or communicate.
• Enrollment in hospice or life expectancy so limited that additional evaluation would not be appropriate per clinician judgment.
• Clinical circumstances where immediate alternative diagnostic pathways supersede study procedures (e.g., acute decompensation requiring urgent management).
• Prior liver or kidney transplant.
• Patient unwilling to undergo prospective testing for liver disease.

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States
• Stanford Healthcare — Palo Alto, California, United States
• Kaiser Permanente — Pleasanton, California, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.